Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
'With proceeds from this PRV sale, we have sufficient cash for more than two years of operating expenses without the need for capital infusion and not accounting for ZEVASKYN sales,' said Joe Vazzano, Chief Financial Officer of Abeona. 'Furthermore, with ZEVASKYN becoming available to treat patients beginning third quarter of 2025, we anticipate becoming profitable in early 2026.'
The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
Stifel was lead financial advisor to Abeona on the transaction. Jefferies also served as financial advisor on the transaction.
About Abeona Therapeutics Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYNTM, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as 'may,' 'will,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'potential,' and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully generate commercial sales of ZEVASKYN and generate future revenue; the successful closing of our sale transaction for the Priority Review Voucher; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Methanex (MEOH) Receives a Buy from Alembic Global
In a report released today, Hassan Ahmed from Alembic Global maintained a Buy rating on Methanex, with a price target of $45.00. The company's shares closed today at $32.84. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ahmed covers the Basic Materials sector, focusing on stocks such as Westlake Corporation, Olin, and Chemours Company. According to TipRanks, Ahmed has an average return of 2.7% and a 45.45% success rate on recommended stocks. In addition to Alembic Global, Methanex also received a Buy from TR | OpenAI – 4o's Nessa Reagwyn in a report issued on July 26. However, on July 24, RBC Capital maintained a Hold rating on Methanex (NASDAQ: MEOH). Based on Methanex's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $896.47 million and a net profit of $111.29 million. In comparison, last year the company earned a revenue of $915.71 million and had a net profit of $52.62 million
Yahoo
an hour ago
- Yahoo
UBS Lifts PT on QUALCOMM Incorporated (QCOM) to $165 From $145, Keeps a Neutral Rating
QUALCOMM Incorporated (NASDAQ:QCOM) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS raised the firm's price target on QUALCOMM Incorporated (NASDAQ:QCOM) to $165 from $145, keeping a Neutral rating on the shares. A technician testing the latest 5G device, demonstrating the company's commitment to innovation. The firm told investors in a research note that it expects a modest upside bias to the company's Q3 results in a backdrop showing solid signs of tariff-related pull-ins for Android and Apple units in the quarter. However, it also added that it does not expect this momentum to be sustained into the second half of the year as pull-ins usually wane, primarily because the end consumption for smartphones and PC has failed to get any better. QUALCOMM Incorporated (NASDAQ:QCOM) develops and commercializes foundational technologies for the wireless industry, including 3G, 4G, and 5G wireless connectivity and high-performance and low-power computing, including on-device AI. While we acknowledge the potential of QCOM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Morgan Stanley Initiates Monday.com (MNDY) with Equal Weight Rating, $330 PT
Ltd. (NASDAQ:MNDY) is one of the best growth stocks to buy and hold for 3 years. Earlier on June 17, Morgan Stanley initiated coverage of while assigning an Equal Weight rating and setting a price target of $330. The firm acknowledged the inherent risks associated with move towards larger enterprise markets, expanding its multi-product offerings, and shifting to a sales-led growth model. net income improved to $58.4 million in Q1 2025, which was up from $31.7 million year-over-year. Additionally, the total employee headcount increased to 2,695, which showed an addition of 187 employees from the previous quarter. Photo by Chris Montgomery on Unsplash Notably, the adoption of AI features saw growth at the company, which is evident from users performing over 26 million AI actions, which is also an increase of over 150% since the end of 2024. However, the full-year 2025 guidance reflects a conservative approach given potential macroeconomic challenges. Ltd. (NASDAQ:MNDY) develops software applications internationally. It provides Work Operating System, which is a cloud-based visual work OS that consists of modular building blocks used and assembled to create software applications and work management tools. While we acknowledge the potential of MNDY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
